VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
VBIV was delisted on the 7th of August, 2024.
130 hedge funds and large institutions have $83.3M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 44 reducing their positions, and 13 closing their positions.
311% more call options, than puts
Call options by funds: $407K | Put options by funds: $99K
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
1% less funds holding
Funds holding: 131 → 130 (-1)
14% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 44
56% less capital invested
Capital invested by funds: $191M → $83.3M (-$108M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.37M |
| 2 |
Renaissance Technologies
New York
|
+$700K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$626K |
| 4 |
BlackRock
New York
|
+$552K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$444K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$13.9M |
| 2 |
Rafferty Asset Management
New York
|
-$1.18M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.17M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$771K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$609K |
VBIV Hedge Fund Activity: Q2 2022 in Review
130 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q2 2022, worth a combined $83.3M — down 56% from $191M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new VBIV positions and 13 closed out — a net gain of 1 holder — while 38 added to existing stakes and 44 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.37M. The largest seller was State Street, cutting an estimated $13.9M.
- 130 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q2 2022, down from 131 in Q1 2022.
- Funds reported $83.3M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q2 2022, down 56% quarter-over-quarter.
- 14 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q2 2022 and 13 closed out, a net change of +1 holder.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q2 2022 was Millennium Management, an estimated $1.37M added.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q2 2022 was State Street, an estimated $13.9M sold.
Based on aggregated 13F filings for Q2 2022.